India, Aug. 13 -- Biopharmaceutical innovation in India is being reshaped by advanced biologics, cell and gene therapies, RNA-based therapeutics, AI-enabled discovery and sophisticated manufacturing platforms. As the science grows more complex, talent readiness is emerging as a key differentiator. India has built a strong foundation in pharmaceuticals, vaccines and biotechnology, supported by a deep pipeline of science and engineering graduates. Its bioeconomy has grown from $ 10 billion in 2014 to $ 195.3 billion in 2025 and is projected to reach $ 300 billion by 2030. Sustaining this momentum will require a workforce equipped for regulated, technology-driven environments where scientific expertise, process understanding, quality systems...